Business Wire

NV-ISACA

15.10.2018 15:37:05 CEST | Business Wire | Press release

Share
9 in 10 Enterprises Report Gaps Between the Cybersecurity Culture They Have and the One They Want

With cybersecurity threats continuing to escalate worldwide, the ISACA/CMMI Institute Cybersecurity Culture Report found that just 5 percent of employees think their organization’s cybersecurity culture is as advanced as it needs to be to protect their business from internal and external threats. More than 4,800 business and technology professionals shared their insights in the global research study, conducted via online polling in June 2018. Results were released today at ISACA’s CSX North America cybersecurity conference in Las Vegas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005149/en/

Cybersecurity culture is a workplace culture in which security awareness and behaviors are integrated into everyone’s daily operations, as well as an executive leadership priority. In a threat-ripe environment, an effective cybersecurity culture can help employees understand their roles and responsibilities in keeping their organizations safe and customer data secure. However, just 34 percent of respondents say they understand their role in their organizations’ cyber culture.

Companies must take an all-hands-on-deck approach to counter cyberattack threats, the report summarizes.

“Enlisting the entire workforce to mitigate an enterprise’s cyber risk is an emerging practice,” says Doug Grindstaff II, SVP of Cybersecurity Solutions at CMMI Institute . “We are hearing a lot of feedback about how organizations can move the needle on employee involvement. It’s challenging, but organizations are rightly concerned by the growing sophistication of cyberattacks.”

Widespread employee involvement correlates strongly with the minority of organizations that have achieved strong satisfaction with their cybersecurity culture. Nine in ten employees (92 percent) at these organizations say that their C-level executives share an excellent understanding of the underlying issues, which may be why they loop-in their employees so well; 84 percent of employees at these organizations say they understand their role in cybersecurity.

Other critical findings include:

  • Many organizations lack the first—and all-important—step toward a cybersecurity culture: 42 percent of organizations do not have an outlined cybersecurity culture management plan or policy.
  • Aligning the entire workforce with the organization’s cybersecurity policies requires significant capital: Organizations that report a significant gap between their current and desired cybersecurity culture are spending just 19 percent of their annual cybersecurity budget on training and tools; organizations that believe their cybersecurity culture is where it is supposed to be are spending more than twice as much (43 percent).

“A key motivator for organizations delaying investing in their cybersecurity cultures is a lack of awareness about the attempted threats and ongoing risks, as well as a lack of awareness about the assets at risk to cybersecurity threats,” said Rob Clyde, NACD Board Leadership Fellow and ISACA Board Chair. “However, individuals tend to underestimate the potential damage and overestimate technology’s ability to limit such incidents. Doing so puts their organizations at serious risk.”

To view the research, visit www.isaca.org/cybersecurity-culture-study .

About ISACA

Nearing its 50th year, ISACA ® (isaca.org ) is a global association helping individuals and enterprises achieve the positive potential of technology. ISACA equips professionals with the knowledge, credentials, education and community to advance their careers and transform their organizations.

Twitter: www.twitter.com/ISACANews

About CMMI ® Institute

A subsidiary of ISACA Enterprises, CMMI Institute (cmmiinstitute.com ) is the global leader in the advancement of best practices in people, process and technology. The Institute provides the tools and support for organizations to benchmark their capabilities and maturity by comparing their operations to best practices and identifying performance gaps.

Twitter: https://twitter.com/CMMI_Institute

Contact:

ISACA Emily Van Camp, +1.847.385.7223 evcamp@isaca.org or Kristen Kessinger, +1.847.660.5512 kkessinger@isaca.org

Link:

ClickThru

Social Media:

https://www.facebook.com/ISACAHQ

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye